Ontology highlight
ABSTRACT:
SUBMITTER: Strumberg D
PROVIDER: S-EPMC3364125 | biostudies-literature | 2012 May
REPOSITORIES: biostudies-literature
Strumberg D D Scheulen M E ME Schultheis B B Richly H H Frost A A Büchert M M Christensen O O Jeffers M M Heinig R R Boix O O Mross K K
British journal of cancer 20120508 11
<h4>Background</h4>In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC).<h4>Methods</h4>Patients received oral regorafenib 60-220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment. Assessments included toxicity, response, pharmacokinetics and pharmacodynamics.<h4>Results</h4>Thirty-eight patients wit ...[more]